Welcome

Pre-Open

RMi Pre-opening: More econs

January 30, 2026

Sucking the” breath” from the alternating share pricing sessions?

Whether or not Thursday's session was a blip; signs of excessive bullishness makes the C&GT sector susceptible to a sell-off

News: Moderna, Inc. (MRNA +$1.56 or +3.44% to $46.86) announced a strategic collaboration with Recordati to advance MRNA's investigational propionic acidemia (PA) therapeutic, mRNA-3927, through the final stages of clinical development and, upon approval, global commercialization. Recordati, based in Milan, Italy, is an international pharmaceutical group that provides treatments across specialty and primary care, and rare diseases, including PA. Through this agreement, MRNA will continue to lead the clinical development of mRNA-3927 through approval and Recordati will lead commercialization

Pre-open Signals: 1 Positive yet passing on others today; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

Out and About

RMi Financing Note: AxoGen (AXGN) Completed an offering of 4 M shares at $31.00

January 25, 2026

AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49%

Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses.

The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions.

Closing Bell

RMi Closing Bell: Wipe-out

January 30, 2026

Volatile week continues as “Econs were the predators <as I wrote>; sucking the” breath” from the alternating share pricing sessions”

End-of-month and a Friday, a down-turn had to happen after this volatile month

News: Ultragenyx Pharmaceutical (RARE -$0.20 or -0.82% to $24.07) has resubmitted its Biologics License Application (BLA) seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA) to the FDA. The submission contains substantial longer-term data on multiple measures of neurologic benefit to support an intermediate clinical endpoint for accelerated approval supported further by CSF heparan sulfate and other biomarker data, as agreed with the FDA during the last clinical review.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!

TGIF

Research Notes

RMi Financing Note: AxoGen (AXGN) Completed an offering of 4 M shares at $31.00

January 25, 2026

AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions.

RMi Research Note: Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA

January 21, 2026

Another Opinion: Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? https://finance.yahoo.com/news/fda-no-trial-stance-deramiocel-111135647.html I am NOT the only DISSENTER! s Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump. https://finance.yahoo.com/news/capricor-therapeutics-capr-still-attractive-052444220.html FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process. CAPR expects to submit updates to the BLA in February 2026 to support continued FDA review. As previously disclosed, CAPR provided topline results from its P3 HOPE-3 clinical study to the FDA in late 2025. Rejected for more data. For all my … <some say> … RANTINGS, I say TRUTH … timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall! STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.

RMi Research Note: Harvard Apparatus GT (OTCQB:HRGN): A new financing attempt?

January 20, 2026

Financing on Deck: Harvard Apparatus RT (OTCQB: HRGN (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” OTCQB: HRGN (closed flat again Monday 1/20 after Friday, 1/16 $0.00 at $1.45) entered into Securities Purchase Agreements with Investors agreeing to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $700 K and a purchase price per share of $1.70. Closed flat $0.00 Friday at $1.45 after Thursday’s +$0.0270 after Wednesday's -$0.10 with 6,980 shares traded after Tuesday’s -$0.38 after Monday’s +$0.01 after Friday’s $0.00) Such a deal, next joke! Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company! Guess who's providing the lipstick for this pig! WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND Accumulated deficit to date = $103.2 M in 12 years ... U.S. investors BEWARE, forewarned is forearmed?

Research Notes

January 25, 2026 RMi Financing Note: AxoGen (AXGN) Completed an offering of 4 M shares at $31.00 AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions. January 21, 2026 RMi Research Note: Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA Another Opinion: Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? https://finance.yahoo.com/news/fda-no-trial-stance-deramiocel-111135647.html I am NOT the only DISSENTER! s Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump. https://finance.yahoo.com/news/capricor-therapeutics-capr-still-attractive-052444220.html FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process. CAPR expects to submit updates to the BLA in February 2026 to support continued FDA review. As previously disclosed, CAPR provided topline results from its P3 HOPE-3 clinical study to the FDA in late 2025. Rejected for more data. For all my … <some say> … RANTINGS, I say TRUTH … timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall! STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals. January 20, 2026 RMi Research Note: Harvard Apparatus GT (OTCQB:HRGN): A new financing attempt? Financing on Deck: Harvard Apparatus RT (OTCQB: HRGN (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” OTCQB: HRGN (closed flat again Monday 1/20 after Friday, 1/16 $0.00 at $1.45) entered into Securities Purchase Agreements with Investors agreeing to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $700 K and a purchase price per share of $1.70. Closed flat $0.00 Friday at $1.45 after Thursday’s +$0.0270 after Wednesday's -$0.10 with 6,980 shares traded after Tuesday’s -$0.38 after Monday’s +$0.01 after Friday’s $0.00) Such a deal, next joke! Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company! Guess who's providing the lipstick for this pig! WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND Accumulated deficit to date = $103.2 M in 12 years ... U.S. investors BEWARE, forewarned is forearmed? January 8, 2026 RegMedInvestors (RMi) Financing Note: Arrowhead Pharmaceuticals (ARWR) priced its offerings of notes, stock and warrants Of $625 M aggregate principal amount of 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock, at a public offering price of $64.50 per share and pre-funded warrants, at an offering price of $64.499 per pre-funded warrant, for up to 1,550,387 shares of common stock ARWR is up +$1.14 or +1.74% to $66.85 Getting it done while it can and still with a positive response January 1, 2026 RegMed Investors (RMi): Happy New Year – 2026 “Last year's words .... belong to last year's language. And next year's words ... await another voice” — TS Eliot

Indication intelligence, analysis and sector perception

Weekend Recap

Earnings